注射用哌拉西林钠他唑巴坦钠致横纹肌溶解1例分析

doi:10.19803/j.1672-8629.20250918

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (9): 1062-1064.
DOI: 10.19803/j.1672-8629.20250918

注射用哌拉西林钠他唑巴坦钠致横纹肌溶解1例分析

邢璐宇, 邢迎红^*, 范文, 张淑翼

天津市第一中心医院重症医学科,国家卫健委危重病急救医学重点实验室,天津市急救医学研究所,天津 300192

收稿日期:2025-12-19 出版日期:2026-09-15 发布日期:2026-09-15
通讯作者: ^*邢迎红,女,硕士,主任医师,重症医学。E-mail: 1965yinghong@sina.com
作者简介:邢璐宇,女,硕士,住院医师,重症医学。
基金资助:
天津市医学重点学科建设项目（TJYXZDXK-3-023C）; 天津市卫生健康科技项目（TJWJ2022XK023）; 河北省中医药管理局科研计划项目（T2025009）

One case of rhabdomyolysis caused by piperacillin sodium and tazobactam sodium for injection

Xing Luyu, Xing Yinghong^*, Fan Wen, Zhang Shuyi

Department of Critical Care Medicine, Tianjin First Central Hospital, Key Laboratory of Critical Care Medicine of the National Health Commission, Tianjin Institute of Emergency Medicine, Tianjin 300192, China

Received:2025-12-19 Online:2026-09-15 Published:2026-09-15

摘要/Abstract

摘要： 目的探讨注射用哌拉西林钠他唑巴坦钠引起的横纹肌溶解,为临床安全用药提供参考。方法分析1例糖尿病性酮症酸中毒（DKA）合并感染患者使用注射用哌拉西林钠他唑巴坦钠抗感染导致横纹肌溶解的病例,结合国内外文献讨论药品不良反应（ADR）发生的临床表现、可能机制、预防等。结果经关联性分析,考虑横纹肌溶解与注射用哌拉西林钠他唑巴坦钠有关。停药后,患者ADR症状缓解出院。结论临床应警惕注射用哌拉西林钠他唑巴坦钠导致横纹肌溶解的风险,尽早识别尽早干预,以免造成严重ADR。

关键词: 注射用哌拉西林钠他唑巴坦钠, 横纹肌溶解, 药品不良反应, 糖尿病性酮症酸中毒

Abstract: Objective To explore the risk of rhabdomyolysis induced by piperacillin sodium and tazobactam sodium for injection and provide a reference for clinical safe medications. Methods One case of rhabdomyolysis caused by piperacillin sodium and tazobactam sodium for injection used to combat infection in a patient with infection complicated with diabetic ketoacidosis (DKA) was analyzed. The clinical manifestations, possible mechanisms, and prevention of adverse drug reactions (ADRs) were explored based on literature. Results Rhabdomyolysis was believed to be linked to piperacillin tazobactam. After discontinuation of the drug, the levels of MYO and CK decreased significantly, and muscle pain disappeared. Conclusion Clinicians should be vigilant about the potential risk of rhabdomyolysis induced by piperacillin sodium and tazobactam sodium for injection. Early detection and prompt interventions are critical to mitigating severe neurological complications.

Key words: Piperacillin Sodium and Tazobactam Sodium for Injection, Rhabdomyolysis, Adverse Drug Reaction, Diabetic Ketoacidosis (DKA)

中图分类号:

R978
R994.11

邢璐宇, 邢迎红, 范文, 张淑翼. 注射用哌拉西林钠他唑巴坦钠致横纹肌溶解1例分析[J]. 中国药物警戒, 2026, 23(9): 1062-1064.

Xing Luyu, Xing Yinghong, Fan Wen, Zhang Shuyi. One case of rhabdomyolysis caused by piperacillin sodium and tazobactam sodium for injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(9): 1062-1064.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250918

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I9/1062

参考文献

[1] Richert Q, Miller N, Cameron S, et al. Updates on rhabdomyolysis: a clinically oriented narrative review[J/OL]. Chest, 2026-01-29. https://pubmed.ncbi.nlm.nih.gov/41619932/.
[2] Zhang Yuanyuan, Zhang Jianrong.Progress on the pathogenesis and treatment in rhabdomyolysis-induced acute kidney injury[J]. Chinese Journal of Disaster Medicine(中华灾害救援医学), 2017, 5(2): 96-100.
[3] Munch M, Granholm A, Jonsson A, et al.Piperacillin/tazobactam versus carbapenems in patients with severe bacterial infections: a systematic review with meta-analysis[J]. Acta Anaesthesiologica Scandinavica, 2023, 67(7): 853-868.
[4] Xin Lili, Zhang Xiangfang, Wang Shuishui.Analysis of 99 cases of adverse reactions of piperacillin sodium and tazobactam sodium for injection[J]. China Licensed Pharmacist(中国合理用药探索), 2022,19(8): 122-126.
[5] Teng C, Baus C, Wilson J, et al.Rhabdomyolysis associations with antibiotics: a pharmacovigilance study of the FDA adverse event repor-
ting system (FAERS)[J]. International Journal of Medical Sciences, 2019, 16(11): 1504-1509.
[6] Puccini V.Antibiotic therapy and athletes: is the mitochondrial dysfunction the real achilles'heel?[J]. Sports (Basel, Switzerland), 2022, 10(9): 131.
[7] Jiang S, Li T, Zhou X, et al.Antibiotic drug piperacillin induces neuron cell death through mitochondrial dysfunction and oxidative damage[J]. Canadian Journal of Physiology and Pharmacology, 2018, 96(6): 562-568.
[8] Lobritz M, Andrews I W, Braff D, et al.Increased energy demand from anabolic-catabolic processes drives β-lactam antibiotic lethality[J]. Cell Chemical Biology, 2022, 29(2): 276-286.
[9] Zhao Haoran, Yu Mingyan, Zhao Haiyun, et al.Quality evaluation of piperacillin sodium and tazobactam sodium for injection[J]. Chinese Journal of Antibiotics(中国抗生素杂志), 2025, 50(3): 256-265.
[10] Kiliaki S.Piperacillin-tazobactam-induced immune thrombocytopenia: a case report[J]. J Pharm Pract, 2023, 36(2): 451-452.
[11] Pan K, Li R, Li Y, et al.Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis[J]. The Journal of antimicrobial chemotherapy, 2025, 80(1): 47-58.
[12] Zhang Hongru, Yang Liping.The adverse reactions of piperacillin: a systematic review[J]. Chinese Journal of Evidence-Based Medicine
(中国循证医学杂志), 2023, 23(2): 191-196.
[13] Du Jing, Li Yonghui, Yan Naxin, et al.Pharmaceutical care of a patient with lung abscess with drug fever and rhabdomyolysis induced
by piperacillin-tazobactam[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(4): 450-452.
[14] Ye D, Sun J, Jiang R, et al.β-lactam antibiotics induce metabolic perturbations linked to ROS generation leads to bacterial impairment[J]. Frontiers in Microbiology, 2024, 15: 1514825.
[15] Zhao A, Guo D, Zhu M, et al.Incidence, characteristics, and risk factors of drug-associated muscle adverse reaction: a retrospective real-world study of inpatients[J]. European Journal of Clinical Pharmacology, 2024, 80(6): 911-918.

注射用哌拉西林钠他唑巴坦钠致横纹肌溶解1例分析

One case of rhabdomyolysis caused by piperacillin sodium and tazobactam sodium for injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	冯思琪, 倪雨晨, 胡冯译, 刘玥, 叶小飞, 郭晓晶. 细胞治疗产品上市后长期安全性监测的国际经验与中国优化路径[J]. 中国药物警戒, 2026, 23(9): 975-981.
[2]	刘红亮, 宋海波, 米岚, 孟康康, 王涛, 漆燕, 贾晋生. 基于大语言模型应用的个例安全性报告数据清洗方法探讨[J]. 中国药物警戒, 2026, 23(9): 1017-1022.
[3]	赵志伟, 柯文缘, 杨雪, 陈晓博, 夏旭东. 1358例碘克沙醇注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(9): 1040-1044.
[4]	潘恩, 崔小康, 徐滨, 荣右明, 范晓, 马晓东, 李霞. 1115例草酸艾司西酞普兰片不良反应报告分析[J]. 中国药物警戒, 2026, 23(9): 1045-1049.
[5]	尚家海, 龙娇娇, 刘雅瑞, 卢圆圆. 注射用尖吻蝮蛇血凝酶致儿童结膜充血2例分析[J]. 中国药物警戒, 2026, 23(9): 1050-1052.
[6]	吴倩, 覃勇, 望庐山, 韩忠宇. 吉非替尼片致心肌炎1例分析[J]. 中国药物警戒, 2026, 23(9): 1053-1055.
[7]	孙玲玲, 方薇, 王雨廷, 李进峰, 杨依磊. 阿昔洛韦咀嚼片致急性重度肝损伤1例分析[J]. 中国药物警戒, 2026, 23(9): 1056-1058.
[8]	王昆, 徐磊, 汪岑, 侯文平, 刘俊保, 苏长海. 地高辛片致舞蹈症1例分析[J]. 中国药物警戒, 2026, 23(9): 1059-1061.
[9]	向群, 傅大莉. 药源性认知障碍的致病药物及疾病风险评估研究进展[J]. 中国药物警戒, 2026, 23(9): 1075-1080.
[10]	吕欣鸽, 刘艾嘉, 武一, 潘晨, 王雨婷, 崔向丽. 免疫检查点抑制剂相关甲状腺功能障碍的多中心病例分析[J]. 中国药物警戒, 2026, 23(8): 892-897.
[11]	李剑屏, 杜宁, 唐敏, 周子原, 左靖. 691例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 904-908.
[12]	白丽琴, 聂红科, 杨淑婷, 蒋晓峰. 214例肌苷注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 909-913.
[13]	张育茂, 刘君波, 罗千江, 谭槟滢, 邓彬, 邢惟青, 李玉珍. 口服复方聚乙二醇电解质散（Ⅱ）肠道准备致呕血2例分析[J]. 中国药物警戒, 2026, 23(8): 931-933.
[14]	高朝政, 赵一帆, 苏丽, 李平. 注射用芦康沙妥珠单抗致癌症患者急性疼痛2例分析[J]. 中国药物警戒, 2026, 23(8): 934-937.
[15]	谢华丽, 关碧茜, 卓羽波, 何洁丽, 陈喆. 注射用芦康沙妥珠单抗致序贯性超敏反应1例分析[J]. 中国药物警戒, 2026, 23(8): 938-940.